Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Optimising cardiac stem cell therapy by finding the best conditions for the cells in the lab and in the heart

Stem cell-derived cardiomyocytes grown as engineered heart tissue (left); stained to shown contractile proteins (centre); and electron microscopy showing stem cell-derived cardiomyocytes grown in a porous collage scaffold (right).

I am afraid we are not taking on any new students as I am heading towards retirement

We are studying cardiac progenitor cells for use in therapy and for disease modelling. We have shown that cardiac progenitor cells, isolated and expanded from biopsy samples of the heart, and induced pluripotent cells, differentiated towards a cardiac phenotype, significantly improved function of the heart after myocardial infarction. However, with both cell types, the cell retention is low and the improvement in function is not large. To improve the efficacy of the cell therapy, we are investigating tissue engineering strategies to deliver cells as a bandage across the infarct scar, and whether addition of hypoxic microRNAs to the cells can increase cell survival after administration to the heart

We are measuring changes in cell metabolism as the cells differentiate into cardiomyocytes. By characterising the metabolism of human induced pluripotent cells that have been differentiated into beating cardiomyocytes, we can explore the use of these cells to detect metabolic side-effects of potential drug compounds or to explore the effect of cellular defects on cardiac metabolism. When the cells are grown as a monolayer, they retain a very immature metabolic profile, so we are growing them as 'Engineered Heart Tissue', where the cells are held in a gel between two flexible posts, so that they have to work to contract. In addition, we change the culture medium to provide a combination of nutrients more representative of that which the cells experience in the heart. We have shown that this induces a metabolic profile more like that of an adult human heart cell and are now going on to explore different disease models in this system.


Our team

Related research themes

We use the full range of modern molecular genetic and imaging techniques to study a range of metabolic areas.
Metabolism & Endocrinology

We use the full range of modern molecular genetic ...

We are recognised internationally for our pioneering approaches to systems biology and to computational modelling of the heart.
Cardiac Sciences

We are recognised internationally for our ...